Immunophenotype is one of the most useful tool for the identification of leukemia subtypes [1] [2] [3] [4] [5] and can be assigned within a few hours after bone marrow sampling.
RARA gene rearrangement [10] [11] [12] [13] , and clinical characteristics of HLA-DR negative non-APL patients have yet to be clarified.
The purpose of this study was to evaluate and compare the characteristics of HLA-DR negative non-APL cases, APL, and HLA-DR positive non-APL cases.
MATERIALS AND MTHODS

Patients
The records and laboratory findings of 114 AML cases admitted at Ewha Womans University Mokdong Hospital between March 1997 and June 2006 were reviewed.
The median age of these patients was 46 yr, ranging from 1 day to 83 yr (mean 46.1, SD 20.1 yr), and 58 were male and 56 female. The diagnosis of AML were made based on the results of morphology, cytochemistry, immunophenotype, cytogenetics, and/or fluorescence in situ hybridization [14, 15] . The diagnosis of disseminated intravascular coagulation (DIC) was made by finding a prolonged prothrombin time, activated partial thromboplastin time, and positive fibrinogen degradation product/ D-dimer with reduced fibrinogen and platelet count. The patients with conditions other than AML that could cause DIC were not included. 
Immunophenotyping
Statistics
Statistic analysis was performed using SPSS software, version 11.0 (SPSS Inc., Chicago, IL, USA). Relations between variables were analyzed using the Fisher exact test for categorical variables and the Student' s t-test for continuous variables. P values of less than 0.05 were considered statistically significant.
RESULT
Incidence of HLA-DR negative AML
Among the 114 AML patients, HLA-DR antigen was not expressed in 39 patients (34%), including 24 non-APL (62%) and 15 APL patients (38%). Among the non-APL patients, 24% of the patients didn' t show HLA-DR expression.
Comparison of HLA-DR negative non-APL and APL
groups (Table 1) The laboratory findings at diagnosis were not statistically different between HLA-DR negative non-APL and APL cases, except leukocyte counts and CD19 expression.
The HLA-DR negative non-APL group showed higher leukocyte counts than did the APL group. CD19 was expressed more frequently in HLA-DR negative non-APL than in APL (P<0.05). Among the HLA-DR negative non-APL, 7 patients had DIC and 2 patients had morphologic features similar to those of APL, i.e., indented nuclei and heavy coarse cytoplasmic granules (a representative example was shown in Fig. 1 ). These 2 cases did not express CD34 and CD19 as well as HLA-DR and showed normal karyotype without PML-RARA rearrangement by a molecular study.
3. Comparison of HLA-DR positive and negative non-APL patients (Table 1) In HLA-DR positive non-APL group, the leukemic cell counts of bone marrow and DIC rates were lower, where-as platelet counts were higher than in HLA-DR negative non-APL group (P<0.05). CD34 was more frequently expressed in the HLA-DR positive group than in HLA-DR negative group.
DISUSSION
In this study, 60% of the HLA-DR negative AML patients were non-APL and 24% of the non-APL patients did not show HLA-DR expression. Other studies reported that the incidence of HLA-DR negative non-APL was 9 to 24% [4, 10, 11] . Taken together, the absence of HLA-DR antigen expression cannot be considered sufficient for establishing a diagnosis of APL.
We found that the laboratory findings at diagnosis were not significantly different between HLA-DR negative non-APL and APL, except for leukocyte counts and CD19 expression. Worthy of note was the finding that 46% of the HLA-DR negative non-APL cases expressed CD19, whereas CD19 was rarely expressed in APL. The Literature review, showed that CD19 antigen was not expressed in any of the 250 APL patients (including microgranular variant) using a 20% cutoff [4, 7, 8, 10] , whereas one study reported CD19 expression in 11% of APL patients [16] . The absence of CD19 may be a useful marker for APL.
A previous study reported that CD34 was expressed in 62% of non-APL and 17% of APL (all microgranular variants) cases [17] . In the present study, CD34 expression was significantly less frequent in APL cases than in non-APL. Furthermore, HLA-DR negative non-APL showed a lower incidence of CD34 expression than did Another study also demonstrated that the incidence of CD34 expression was higher in HLA-DR positive non-APL (79%) than in HLA-DR negative non-APL patients (17%) [18] . Especially, 10% of non-APL patients were negative for both CD34 and HLA-DR [17] . One author reported that invaginated nuclear morphology was associated with loss of HLA-DR and CD34 expressions in non-APL [19] . These results suggested that absence of HLA-DR antigen was accompanied by absence of CD34 antigen in AML. In the present study, positive predictive value was found to be further enhanced when the expressions of CD19 and CD34 were taken into account with HLA-DR negativity for predicting APL (40% for only HLA-DR negativity; 46% for HLA-DR and CD34 negativity; and 57% for HLA-DR, CD34, and CD19 negativity).
We found that the leukemic cell counts of bone marrow and DIC rates were higher in HLA-DR negative non-APL than in HLA-DR positive non-APL group, whereas platelet counts were higher in HLA-DR positive non-APL group (P<0.05). It has been reported that treatment response of HLA-DR negative patients is similar to those of HLA-DR positive non-APL [10] .
Furthermore, we found that two cases among 24 HLA-DR negative non-APL cases showed morphologies similar to those of APL, and these cases were negative for both CD19 and CD34. Thus, cytogenetic and molecular studies were found necessary in such cases for an accurate diagnosis. Other authors have also reported that cells from HLA-DR negative non-APL patients resemble those of hypogranular variant APL, whereas morphologic features resembling APL are not present in any HLA-DR positive AML patients [10] . Moreover, some investigators have described that HLA-DR negative AML patients who seem to have APL variants based on morphology and immunophenotype, are re-classified as non-APL after cytogenetic and molecular analyses [12, 13] . Taken together, HLA-DR negative non-APL may show the similar characteristics to APL, which may make it more difficult to differentiate non-APL, especially, those resembling APL, from APL. 
